If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.
After falling short in a label-extension trial Johnson & Johnson still sees a path forward for its blood thinner in preventing venous thromboembolism.
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Alnylam has secured its first approval, but history suggests that launch will be far from easy.
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.